Merck signs exclusive global license with SciBrunch for KRAS G12D drug SPR2015 in USD 2.13 billion deal

Merck signed an exclusive global license with SciBrunch Therapeutics for SPR2015, a preclinical oral KRAS G12D (ON) inhibitor. Deal grants worldwide rights to develop, manufacture, commercialize SPR2015. SciBrunch to receive USD 400 million upfront. * Milestone payments could lift total potential deal value to USD 2.13 billion across multiple indications. Merck expects a USD 400 million pre-tax charge in Q3 2026, about USD 0.13 per share. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via (Ref. ID: 202609280645BIZWIRE_USPR_____20260928_BW125137) on September 28, 2026, and is solely responsible for the information contained therein. (C)